MEK Inhibition Remodels the Immune Landscape of Mutant KRAS Tumors to Overcome Resistance to PARP and Immune Checkpoint Inhibitors
Open accessPublished version of a preprint
The DOI matches its Crossref record; 52 of the 54 references it cites were found in a registry or an index.
Abstract
Mutant KRAS tumors are associated with poor outcomes, at least in part, due to decreased therapeutic sensitivity. Here, we show that KRAS mutations are associated with resistance to monotherapy and combination therapy with PARP inhibitors (PARPi) and immune checkpoint blockade with anti–PD-L1 antibodies. In mutant KRAS tumors, inhibition of KRAS signaling with MEK inhibitors (MEKi) triggered and amplified PARPi-induced DNA damage, cytosolic double-stranded DNA accumulation, STING pathway activation, and CD8+ T-cell recruitment. Moreover, MEKi decreased myeloid-derived suppressor cell infiltration, in part, by inhibiting IL6 and GMCSF production. Importantly, addition of MEKi to PARPi and anti–PD-L1 resulted in marked tumor inhibition in immunocompetent mutant KRAS tumor models. This study provides the underlying mechanistic data to support evaluation of PARPi, MEKi, and anti–PD-L1 combination in clinical trials of mutant KRAS tumors. Significance: This study provides key insights into the potential for using MEKi combined with PARPi and anti–PD-L1 for the treatment of all mutant KRAS tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, recently published preclinical data suggest that KRAS mutations enhance resistance to PARPi and anti-PD-L1 therapy in CRC PDX models, which may be related to PMEK1/2 and pMAPK, and the addition of MEKi to the combination of PARPi and anti-PD-L1 therapy reverses drug resistance in KRAS-mutated tumors [23].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [23]
In the citing paper
“In addition, recently published preclinical data suggest that KRAS mutations enhance resistance to PARPi and anti-PD-L1 therapy in CRC PDX models, which may be related to PMEK1/2 and pMAPK, and the addition of MEKi to the combination of PARPi and anti-PD-L1 therapy reverses drug resistance in KRAS-mutated tumors [23].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448 · cited 2×
“Interestingly, MAPK pathway gene signatures are enriched in anti–PD-1 nonresponding patients (16).”
BackgroundThe Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277 · cited 1×
“Recently, AMG 510 (49) or MRTX849 (50), two selective KRAS inhibitors, have been shown to enhance immune cell infiltration and render tumors sensitive to immunotherapy.”
BackgroundThe multifaceted roles of PARP1 in DNA repair and chromatin remodelling
Ray Chaudhuri, A., & Nussenzweig, A. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.53 · Cited by 1,786 · cited 1×
“PARPi have been approved for treatment of HR defective (HRD) tumors, including ovarian, breast, pancreatic, and prostate cancers (2).”
BackgroundCGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING.
Ablasser, A., Goldeck, M., Cavlar, T., Deimling, T., Witte, G., Röhl, I., Hopfner, K.-P., Ludwig, J., & Hornung, V. (2013) · Nature · doi:10.1038/nature12306 · Cited by 1,695 · cited 1×
“MEKi and combination therapy induce DNA damage and cytosolic dsDNA accumulation in KRAS-mutant cells The presence of cytosolic dsDNA triggers cGAS/STING-mediated innate immune responses (34).”
BackgroundOlaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Kaufman, B., Shapira-Frommer, R., Schmutzler, R. K., Audeh, M. W., Friedlander, M., Balmaña, J., Mitchell, G., Fried, G., Stemmer, S. M., Hubert, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2728 · Cited by 1,671
Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304 · cited 2×
“Recently, AMG 510 (49) or MRTX849 (50), two selective KRASG12C inhibitors, have been shown to enhance immune cell infiltration and render tumors sensitive to immunotherapy.”
BackgroundThe emerging role of lysophosphatidic acid in cancer
Mills, G. B., & Moolenaar, W. H. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1143 · Cited by 1,094
Self-citationPaweletz, C. P., Charboneau, L., Bichsel, V. E., Simone, N. L., Chen, T., Gillespie, J. W., Emmert-Buck, M. R., Roth, M. J., Petricoin III, E. F., & Liotta, L. A. (2001) · Oncogene · doi:10.1038/sj.onc.1204265 · Cited by 956
Frederick, D. T., Piris, A., Cogdill, A. P., Cooper, Z. A., Lezcano, C., Ferrone, C. R., Mitra, D., Boni, A., Newton, L. P., Liu, C., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1630 · Cited by 944
Research works printed but not linked: 1
- Wang, 2016, Targeting YAP-dependent MDSC infiltration impairs tumor progression, Cancer Discov, 6, 80, 10.1158/2159-8290.CD-15-0224 · DOI · Paper page
Cited by
Lin, H., Liu, C., Hu, A., Zhang, D., Yang, H., & Mao, Y. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01544-7 · Cited by 392
Self-citationTherapy resistance: opportunities created by adaptive responses to targeted therapies in cancer
Labrie, M., Brugge, J. S., Mills, G. B., & Zervantonakis, I. K. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00454-5 · Cited by 369
Self-citationWang, Q., Bergholz, J. S., Ding, L., Lin, Z., Kabraji, S. K., Hughes, M. E., He, X., Xie, S., Jiang, T., Wang, W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30568-1 · Cited by 258
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
Petroni, G., Buqué, A., Coussens, L. M., & Galluzzi, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00415-5 · Cited by 160
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Self-citation
Metadata
- Authors
- Yang, B., Li, X., Fu, Y., Guo, E., Ye, Y., Li, F., Liu, S., Xiao, R., Liu, C., Lu, F., Huang, J., Qin, T., Han, L., Peng, G., Mills, G. B., Sun, C., & Chen, G.
- Affiliations
- Tongji Hospital (CN)
- The University of Texas Health Science Center at Houston (US)
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Sun, Chaoyang
- Chen, Gang
- ORCID
- Venue
- Cancer Research
- Published
- 2021-02-15
- Volume
- 81
- Issue
- 10
- Pages
- 2714-2729
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- PMC
- PMC8265237
- OpenAlex
- W3132990780
- Cited by
- 55
- References
- 54
- Citations by year
- 2026: 7 · 2025: 12 · 2024: 15 · 2023: 9 · 2022: 11 · 2021: 1
- FWCI
- 3.28
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Nature and Science Foundation of China (81572569, 81874106, 81402163, 81974408)
- National Key R&D Program of China (2016YFC1303100)
- NIH (P50CA217685, U01 CA217842)
- Ovarian Cancer Research Foundation
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- mutant KRAS, MEK inhibitors, PARP inhibitors, PD-L1 inhibitors, immune checkpoint blockade, drug resistance, STING pathway, cytosolic DNA, CD8+ T cells, myeloid-derived suppressor cells, interleukin-6, GM-CSF, combination therapy, tumor immune microenvironment
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Myeloid-Derived Suppressor Cells, Immune Checkpoint Inhibitors, Animals, Breast Neoplasms, Colonic Neoplasms, Drug Therapy, Combination, Female, Humans, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Nude, Mutation, Tumor Cells, Cultured, Signal Transduction, Gene Expression Regulation, Neoplastic, Proto-Oncogene Proteins p21(ras), Mice, SCID, Mice, Inbred NOD, Apoptosis, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Protein Kinase Inhibitors, MAP Kinase Kinase 1, Cell Proliferation, Mice, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MEK Inhibition Remodels the Immune Landscape of Mutant KRAS Tumors to Overcome Resistance to PARP and Immune Checkpoint Inhibitors. https://app.cochat.ai/papers/10.1158/0008-5472.can-20-2370
- The paper
- Yang, B., Li, X., Fu, Y., Guo, E., Ye, Y., Li, F., Liu, S., Xiao, R., Liu, C., Lu, F., Huang, J., Qin, T., Han, L., Peng, G., Mills, G. B., Sun, C., & Chen, G. (2021). MEK Inhibition Remodels the Immune Landscape of Mutant KRAS Tumors to Overcome Resistance to PARP and Immune Checkpoint Inhibitors. Cancer Research. https://doi.org/10.1158/0008-5472.can-20-2370
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.